Nyxoah(US:NYXH)2026-03-19 21:30Financial Data and Key Metrics Changes - In Q4 2025, gross revenue was EUR 6.3 million before deferrals, resulting in net revenue of EUR 5.6 million, compared to EUR 1.3 million in Q4 2024, indicating significant growth driven by the U.S. commercial launch [13] - For the full year 2025, gross revenue was EUR 11 million, leading to net revenue of EUR 10 million, a 122% increase from EUR 4.5 million in 2024 [14] - Gross margin for Q4 2025 was 64%, while the full year gross margin was 63% [13][14] - Total operating loss for Q4 2025 was EUR 18.6 million, relatively stable compared to EUR 18.3 million in Q4 2024 [13] - Total operating loss for the full year 2025 was EUR 83.5 million, up from EUR 58.8 million in 2024, reflecting increased commercialization activities [14][15] Business Line Data and Key Metrics Changes - The U.S. commercial launch generated approximately EUR 3.5 million of net revenue in Q4 2025, with $4.5 million in revenue generated from the first full quarter of launch [13][5] - 145 surgeons were trained across 125 high-volume hypoglossal nerve stimulation accounts in the U.S. [6] - 57 Value Analysis Committee approvals were received, with no rejections to date [6][7] Market Data and Key Metrics Changes - The U.S. market is the primary growth driver, with international markets contributing consistently, particularly in Germany, the UK, and the Middle East [12] - Medicare reimbursement for Genio has been consistent, representing 10% of the business, while commercial payers account for approximately 90% [9][10] Company Strategy and Development Direction - The company aims to continue executing its U.S. commercial launch, having increased its sales force to 40 sales reps covering 200 of the top 400 hypoglossal nerve stimulation accounts [17] - Plans include expanding internal manufacturing to strengthen competitive position and improve gross margins [17] - The company is preparing for a PMA supplement submission based on 12-month ACCCESS study data, potentially leading to U.S. label expansion in early 2027 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the U.S. launch momentum and the opportunity ahead, with expectations of 25% sequential growth in U.S. net revenue for Q1 and Q2 2026 [16] - The reimbursement environment is viewed as a normal maturation of an established therapy, with clarity on facility fees expected to support further adoption [11] Other Important Information - The company has a cash position of EUR 48 million as of December 31, 2025, with an expected cash burn of approximately EUR 20 million per quarter in the near term [15][30] - The introduction of new C-codes for AGNS by CMS is anticipated to facilitate billing for traditional Medicare patients [10] Q&A Session Summary Question: Status of Value Analysis Committee submissions and account activations - Management confirmed 120 VAC submissions with 57 approvals, expecting more approvals in Q1 2026 [20][21] Question: Timing for ACCCESS study data and PMA supplement submission - The 12-month data will be available by the end of June 2026, with submission planned for Q1 2027 [23][25] Question: Cash burn rate and guidance for 2026 - Cash burn is approximately EUR 20 million per quarter, expected to decrease as revenue traction increases [29][30] Question: Competitor's coding strategy and implant numbers - Management indicated plans to pursue dedicated coding for Genio, with no specific implant numbers disclosed but revenue figures suggest a strong sales performance [31][34] Question: Patient demographics for Genio implants - Patients are primarily coming from established referral networks, with many choosing Genio for its minimally invasive design and upgradeable features [59]